Wu CW, Liao PC, Lin C, Kuo CJ, Chen ST, Chen HI, Kuo YM
Importantly, the current evidence supporting this approach is largely indirect and derived from studies conducted in patients with established PsO and metabolic comorbidities, rather than in well-characterized early PsA cohorts.An additional and largely underexplored aspect concerns the safety of combining GLP-1RAs with bDMARDs
On the other hand, the concept of non-genomic or cytoplasmic response was introduced in 1967, when Szego and Davis observed an increase in cyclic adenosine monophosphate (cAMP) in the MCF-7 breast cancer cell line pretreated with estrogens (Szego and Davis, 1967)
As if April 17th, I have lost 37 pounds
doi: 10.1016/j.mehy.2012.04.016 177 ParkerJOBrienCHawrelakJ